Groundbreaking Data from ADVANCE-DK Registry

At the recent TCT 2024 conference, groundbreaking data from the ADVANCE-DK registry highlighted the impressive long-term outcomes associated with HeartFlow's innovative technology, including FFRCT (Fractional Flow Reserve computed tomography) and advanced plaque analysis. The findings reveal that these tools not only aid in immediate diagnostics but also in assessing long-term risks of coronary artery disease (CAD).

Impact on Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)

In a related study titled “Usefulness of FFRCT to Exclude Hemodynamically Significant Lesions in High-Risk NSTE-ACS,” researchers confirmed that lesion-specific FFRCT significantly reduces the need for unnecessary invasive procedures in patients experiencing non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Astonishingly, the data indicated that this approach could have prevented 54% to 64% of needless invasive assessments in high-risk groups. When evaluating lesions, FFRCT demonstrated superior performance compared to CCTA alone, with an area under the curve (AUC) of 0.84 compared to 0.65, paving the way for reduced unnecessary invasive coronary angiography.

Insights from HeartFlow's Chief Medical Officer

Dr. Campbell Rogers, Chief Medical Officer of HeartFlow, emphasized the value of these findings: "The ADVANCE-DK data show that our technologies extend beyond identifying immediate CAD risks to measure long-term residual risks. Our lesion-specific FFRCT offers a vital advantage in steering clear of unnecessary tests. With HeartFlow's tools, clinicians gain crucial insights that traditional diagnostic methods have long overlooked."

The Urgency of Cardiovascular Disease Management

The urgency of such advancements cannot be overstated. Cardiovascular diseases continue to be the leading cause of mortality worldwide, affecting both genders. Surveys reveal that a staggering four out of five heart attacks and strokes are preventable with proper lifestyle changes, especially when high-risk patients are identified early. By understanding the intricacies of plaque burden—locations, amounts, and types of plaques in coronary arteries—medical professionals can pinpoint patients who are at greater risk of fatal heart attacks.

HeartFlow's Commitment to Innovation

HeartFlow is at the forefront of combating heart disease through collaboration with healthcare providers, ensuring that high-quality clinical evidence supports their innovative approaches. The technology has already made strides in over 1,300 medical institutions globally, and the company is tirelessly working to expand access to its advanced solutions for a wider patient demographic.

Pioneering Precision Coronary Care

HeartFlow stands as a pioneering force in precision coronary care, equipped with the only AI-driven, non-invasive integrated heart care solution within the CCTA pathway. Their groundbreaking FFRCT technology, now backed by the ACC/AHA Chest Pain Guideline, continues to reshape how CAD is diagnosed and managed. With a portfolio of non-invasive technologies, including FFRCT Analysis, RoadMap™ Analysis, and Plaque Analysis, HeartFlow has influenced the diagnostic and management strategies for over 250,000 patients, supported by more than 500 peer-reviewed studies.

Hope for Patients and Healthcare Professionals

In a world where heart disease strikes swiftly and without warning, the promise of HeartFlow’s technology offers much-needed hope for patients and healthcare professionals alike.